Acessa Health

History

2020: Hologic purchased Acessa Health

At the end of August, 2020 Hologic announced acquisition developer company of remedies for myoma Acessa Health for the amount about $80 million. The Acessa ProVu system should add the products MyoSure the Hologic companies intended for gisteroskopichesky removal uterus myomas.

Acessa ProVu of production Acessa Health is completely the integrated laparoscopic system which combines radio-frequency ablation with the ultrasonography advanced mechanisms and mappings. These functions allow doctors effectively influence benign myomas of a uterus. Clinical researches showed that the miniinvasive Acessa ProVu system it is safe for patients and represents a qualitative alternative hysterectomies and miomektomiya. Radio-frequency ablation of myoma threatens also provides with smaller blood loss faster recovery, than standard methods of treatment.

Hologic purchased the developer of technology of treatment of myoma using ultrasonography

Acquisition will cost Hologic $80 million, but the transaction also means additional payments depending on future growth income. By Hologic estimates, in 2021 financial year Acessa revenue Health will make about $13 million and will begin to make profit already in 2022. In turn cofounder and CEO of Acessa Kim Rodriguez Health noted that under the direction of Hologic and thanks to its commercial programs the Acessa ProVu system can quickly become the standard of treatment of benign myoma of a uterus.

Acessa Health represents the best technology for removal of myoma of a uterus which improves results of treatment of patients and perfectly GYN Surgical fits into our business, - the chairman, the president and the chief executive officer of Hologic Steve MacMillan told. - This purchase will be approved with our purposes on capital allocation.[1]

Notes